thermogenesis.com (THMO) - Ekuitas Perusahaan

ThermoGenesis (THMO) possesses moderate pricing power over its laboratory systems, where demand is sustained by the regular procurement of components. This chart of stock quotes, reaching the value of 0.00, illustrates the dynamics of the blood and stem cell automation business, whose growth relies on the sale of consumables. However, management is facing a liquidity shortage and challenges in software monetization.

To minimize investment risks, it is necessary to decouple market volatility from the issuer's tangible assets. This calculation captures the net asset value minus liabilities, and the analysis of the book capitalization reflects the stability of the ThermoGenesis (THMO) base, bolstered by centrifugation patents and FDA protection, which guarantees the high value of the company's tangible resources even amidst external shocks.